Related by context. All words. (Click for frequent words.) 76 PXD# 74 Perifosine 73 IMC A# 72 HGS ETR1 72 HGS ETR2 72 INCB# [001] 72 ganetespib 71 AP# [003] 71 elotuzumab 71 voreloxin 71 OXi# 71 BAY #-# 71 deforolimus 71 Traficet EN 71 alvespimycin 71 pralatrexate 71 enzastaurin 71 Bortezomib 71 eniluracil 70 Panzem R NCD 70 Azedra 70 CYT# 70 otelixizumab 70 GRN#L 70 obatoclax 70 Carfilzomib 69 AEG# 69 vosaroxin 69 PEG SN# 69 #ME# 69 Marqibo 69 oral prodrug 69 ISTODAX 69 tamibarotene 69 Cloretazine R VNP#M 69 MEK inhibitor 69 mapatumumab 69 Panzem R 69 forodesine 69 Amrubicin 69 LEP ETU 69 RDEA# 69 Archexin 69 ASONEP 69 HuMax CD4 69 Symadex 68 YONDELIS 68 entinostat 68 perifosine 68 tezampanel 68 HuMax CD# 68 JAK inhibitor 68 Sym# 68 XL# [003] 68 IAP inhibitors 68 tanespimycin 68 Tamibarotene 68 TELCYTA 68 PLK1 SNALP 68 MEK inhibitors 68 Exherin TM 68 investigational humanized monoclonal antibody 68 Voreloxin 68 Chemophase 68 HuLuc# 68 CR# vcMMAE 67 Onconase 67 R#/MEM # 67 pomalidomide 67 HGS# 67 CCX# 67 CYC# 67 sapacitabine 67 Atiprimod 67 anticancer agent 67 Omacetaxine 67 HCD# [002] 67 DAVANAT R 67 PSN# [002] 67 rNAPc2 67 IL# PE#QQR 67 MGCD# [002] 67 TAFA# 67 Tyrima 67 Amigal 67 Bezielle 67 JAK1 67 Gemzar ® 67 amrubicin 67 lintuzumab 67 ICA # 67 Panzem 67 #D#C# 67 mitogen activated ERK kinase 67 belinostat 67 liposomal formulation 67 Cloretazine ® 67 INCB# [002] 67 MDV# 67 pertuzumab 67 ELACYT 67 Triolex 67 alvimopan 67 tesetaxel 66 CoFactor 66 MAGE A3 ASCI 66 phase IIa clinical 66 histone deacetylase HDAC inhibitor 66 Phase Ib 66 BCX# 66 HuMax EGFr 66 anti leukemic 66 anticancer compound 66 Phase IIb trials 66 Amplimexon 66 orally administered inhibitor 66 registrational 66 tesmilifene 66 atacicept 66 PDE4 inhibitor 66 Proxinium TM 66 NGX# 66 veltuzumab 66 Dapagliflozin 66 Alocrest 66 IMA# 66 XmAb# 66 KRN# 66 Neuradiab 66 XL# XL# 66 mertansine 66 CORT # 66 AQ4N 66 ixabepilone 66 PEG Interferon lambda 66 Blinatumomab 66 torezolid phosphate 66 JAK2 inhibitor 66 Troxatyl 66 phase IIb clinical 66 elacytarabine 66 OMP #M# 66 L BLP# 66 HER2 positive metastatic breast 66 AeroLEF TM 66 EOquin 66 IMC #B 66 MNTX 66 docetaxel Taxotere R 66 Plicera 66 DAVANAT ® 66 ISIS # 66 DAVANAT 66 Allovectin 7 R 66 Trastuzumab 66 RGB # 65 EndoTAG TM -1 65 sunitinib malate 65 Phase Ib II 65 CA4P 65 Androxal TM 65 axitinib 65 PDX pralatrexate 65 Tarceva TM 65 ATL# [001] 65 AEGR 65 radiation sensitizer 65 OvaRex R 65 vidofludimus 65 Asentar 65 CD# antibody [001] 65 talactoferrin 65 Aplidin R 65 FOLOTYN 65 Aplidin 65 ENMD # 65 HspE7 65 receptor tyrosine kinase inhibitor 65 TREANDA 65 Phase 2a trial 65 PSMA ADC 65 PRTX 65 Belinostat 65 MOZOBIL 65 DXL# 65 Bicifadine 65 blinatumomab 65 PI3K/Akt pathway inhibitor 65 carfilzomib 65 PNP inhibitor 65 Targretin 65 Cloretazine 65 Pralatrexate 65 Annamycin 65 Stedivaze 65 hematological malignancies 65 ONCONASE 65 dacetuzumab 65 TACI Ig 65 Dacogen injection 65 Xanafide 65 Fibrillex TM 65 PS# [001] 65 bortezomib Velcade 65 CRx 65 Cethrin 65 Phase Ib study 65 Seliciclib 65 NXL# 65 seliciclib 65 antitumor activity 65 immunomodulatory 65 methylnaltrexone 65 SAR# [004] 65 Personalized Immunotherapy 65 vorinostat 65 sodium glucose cotransporter 65 Talabostat 65 targeting CD# 65 Icatibant 65 decitabine 65 Hematide ™ 65 Ozarelix 65 metaglidasen 65 Glufosfamide 65 HCV protease inhibitor 65 XYOTAX TM 65 TRAIL receptor antibodies 65 EOquin TM 65 orally bioavailable 65 polymerase inhibitors 65 trabectedin 65 ATL# [002] 65 ADVEXIN 65 vascular disrupting agents 65 epothilone 65 Azedra TM 65 AZD# 65 romidepsin 65 histone deacetylase inhibitor 65 CUDC 65 Zolinza 65 phase IIb trial 65 ZOLINZA 65 RG# [001] 65 PROMACTA 65 IAP inhibitor 64 PRT# 64 HDAC Inhibitor 64 OncoVEX GM CSF 64 zanolimumab 64 TYZEKA 64 CB2 selective receptor agonist 64 TRO# 64 GALNS 64 LY# [003] 64 taxane 64 GSK# [001] 64 APOPTONE 64 VAPRISOL 64 ularitide 64 lesinurad 64 Allovectin 7 ® 64 TLK# 64 2 methoxyestradiol 64 ofatumumab 64 clofarabine 64 mGluR5 negative 64 CD# CEA 64 registrational trial 64 Golimumab 64 Imprime PGG 64 TYKERB 64 FOLOTYN ® 64 humanized anti 64 Phase 2b trial 64 BRAF inhibitor 64 Phase 2b Clinical Trial 64 TELINTRA 64 TG# [003] 64 ZEVALIN 64 ridaforolimus 64 brentuximab vedotin SGN 64 MEK inhibitor RDEA# 64 Lenocta 64 Tanespimycin 64 PCK# 64 talabostat 64 delafloxacin 64 non nucleoside HCV 64 trastuzumab DM1 T DM1 64 ALN TTR 64 satraplatin 64 R#/MEM 64 DermaVir Patch 64 Iloperidone 64 Nexavar ® 64 PANVAC VF 64 Clofarabine 64 Irinotecan 64 huC# DM4 64 angiogenesis inhibitor 64 Phase #b/#a 64 TRIOLEX 64 proteasome inhibitor 64 HCV protease 64 custirsen 64 dose cohorts 64 Elagolix 64 valopicitabine 64 docetaxel Taxotere ® 64 Phase Ib clinical trials 64 xanthine oxidase inhibitor 64 rilonacept 64 nonclinical studies 64 galiximab 64 AZILECT R 64 OMP #R# 64 Phase #b/#a clinical 64 bortezomib 64 erlotinib Tarceva ® 64 Ceflatonin R 64 Serdaxin 64 ALN RSV# 64 XL# XL# XL# XL# 64 sorafenib Nexavar 64 sorafenib tablets 64 MGd 64 APF# 64 SUTENT 64 depsipeptide 64 eltrombopag 64 virus HCV protease inhibitor 64 MyVax R 64 ongoing Phase 1b 64 Vilazodone 64 lenalidomide Revlimid R 64 lorvotuzumab mertansine 64 TOCOSOL Paclitaxel 64 Antiangiogenic 64 phase Ib 64 Dasatinib 64 ISENTRESS 64 LE SN# 63 Aurora kinase 63 PrevOnco ™ 63 Pazopanib 63 ponatinib 63 cilengitide 63 BiTE 63 relapsed multiple myeloma 63 celgosivir 63 TORISEL 63 DOS# 63 peripherally acting 63 novel histone deacetylase 63 EFAPROXYN 63 BiTE antibody 63 HQK 63 CCR5 antagonist 63 IgG1 monoclonal antibody 63 teduglutide 63 glufosfamide 63 Cloretazine R 63 milatuzumab 63 anti EGFR antibody 63 selective androgen receptor modulator 63 fosbretabulin 63 Romidepsin 63 bevacizumab Avastin ® 63 panitumumab 63 NKTR 63 HDAC inhibitor 63 PROVENGE sipuleucel T 63 Aflibercept 63 Factor VIIa 63 proteasome inhibitors 63 Phase III Clinical Trial 63 BiovaxID TM 63 BNC# 63 CINOD 63 Exelixis compounds 63 lomitapide 63 cannabinor 63 Neulasta ® 63 Tesetaxel 63 IRX 2 63 Sapacitabine 63 novel anticancer 63 Xcytrin 63 MAXY G# 63 candidate deforolimus 63 dasatinib 63 PLX# 63 6R BH4 63 SPRYCEL ® 63 pharmacokinetic interactions 63 Azixa 63 Cintredekin Besudotox 63 Phase #/#a trial 63 neratinib 63 Specifid 63 Chrysalin 63 IMGN# 63 ASA# 63 PEG PAL 63 Phase 2a 63 SNT MC# 63 Apoptone 63 gefitinib Iressa 63 Mipomersen 63 T DM1 63 glucagon receptor 63 telomerase therapeutic 63 RhuDex ® 63 dose escalation 63 Phase 1b 63 Virulizin R 63 gemcitabine Gemzar 63 Aganocide 63 visilizumab 63 XP# XP# 63 pan HDAC inhibitor 63 ZK EPO 63 lintuzumab SGN 63 GAP #B# 63 Phenoptin 63 xenograft models 63 FavId 63 Cetrorelix 63 Ambrisentan 63 elesclomol 63 EZN 63 Epratuzumab 63 reslizumab 63 Cethromycin 63 tyrosine kinase inhibitor 63 tivozanib 63 Phase IIB 63 alkylating agent 63 investigational monoclonal antibody 63 generation Hsp# inhibitor 63 Actimmune ® 63 LymphoStat B 63 XL# XL# XL# 63 Preclinical studies suggest 63 Inhalation Solution 63 PrevOnco 63 Pemetrexed 63 Exelixis XL# 63 thymalfasin 63 Taxotere ® 63 cancer immunotherapies 63 ONCONASE R 63 ON #.Na 63 dextromethorphan quinidine 63 panitumumab Vectibix 63 Ocrelizumab 63 daclizumab 63 FTY# 63 NEUGENE 63 Varespladib 63 SCH # 63 Phase IIa trial 63 OvaRex ® MAb 63 ENMD 63 imetelstat 63 Excellarate 63 GW# [003] 63 Onco TCS 63 Locteron 63 Aurora Kinase 63 Genasense R oblimersen 63 CD# monoclonal antibody 63 evaluating tivozanib 63 dasatinib Sprycel ® 63 Pimavanserin 63 TBC# 63 Genz # 63 dose escalation Phase 62 seliciclib CYC# 62 Quinamed 62 ALKS 62 picoplatin 62 Phase 2b Trial 62 paclitaxel Taxol ® 62 PF # [001] 62 pegfilgrastim 62 Debio 62 Civacir 62 incyclinide 62 nab paclitaxel 62 Ceflatonin 62 Erlotinib 62 refractory chronic lymphocytic 62 PRX # 62 HCV protease inhibitors 62 preclinical studies 62 nucleoside 62 selective modulator 62 Nanobody 62 Phase IIIb clinical 62 Phase III Clinical Trials 62 Clolar 62 trastuzumab Herceptin R 62 Myocet 62 pradefovir 62 eprotirome 62 bardoxolone 62 Alpharadin 62 Viprinex 62 Phase 2b 62 leading oral taxane 62 teriflunomide 62 oral isoform selective HDAC 62 ONTAK 62 CEQ# 62 menadione 62 brostallicin 62 mTOR inhibitors 62 Shigamabs ® 62 ProLindac 62 relapsed refractory multiple myeloma 62 selective inhibition 62 Tarvacin TM 62 palifosfamide 62 MLN# 62 small molecule defensin 62 ZADAXIN ® 62 registrational studies 62 AVN# [001] 62 FUSILEV ® 62 oral antiviral 62 StemEx 62 Guanilib 62 posaconazole 62 Harbor BioSciences 62 cMET 62 Phase 1b trial 62 ALN VSP 62 Rebif ® 62 thalidomide Thalomid 62 IMP# 62 novel VDA molecule 62 TKM ApoB 62 Phase IIa trials 62 Palifosfamide 62 LHRH antagonist 62 Reolysin 62 Neurodex 62 preclinically 62 Pivotal Phase 62 docetaxel chemotherapy 62 CBLC# 62 BRIM2 62 OPAXIO 62 tezampanel NGX# 62 DOXIL 62 Homspera 62 Natalizumab 62 HRPC 62 endothelin receptor antagonists 62 cediranib 62 Cimzia ® certolizumab pegol 62 Methylnaltrexone 62 Cannabinor 62 adecatumumab 62 ARRY # 62 OMAPRO 62 cathepsin K inhibitor 62 urocortin 2 62 Hsp# Inhibitor 62 Zenvia TM 62 JAK inhibitors 62 histamine dihydrochloride 62 IDX# 62 compound INCB# 62 RSD# 62 novel immunomodulatory 62 Vandetanib 62 targeted antifolate 62 SinuNase 62 MAXY alpha 62 Luteinizing Hormone Releasing Hormone 62 targeted radiotherapeutic 62 ARIKACE ™ 62 Androxal ® 62 Vidaza azacitidine 62 Phase 2b study 62 ALN TTR# 62 Phase Ib clinical 62 AVE# 62 Granulocyte Colony Stimulating Factor 62 Vidaza 62 Curaxin CBLC# 62 Eltrombopag 62 investigational compound 62 Genasense oblimersen sodium Injection 62 Phase IIb Trial 62 huN# DM1 62 Elotuzumab 62 nicotinic alpha 7 62 refractory gout 62 elagolix 62 uric acid lowering 62 brentuximab vedotin 62 biologic therapy 62 Meets Primary Endpoint 62 Tarvacin 62 SinuNase TM 62 OncoVEX 62 bevacizumab Avastin 62 tubulin inhibitor 62 small molecule Hedgehog 62 Urocidin 62 TriRima 62 cintredekin besudotox 62 Ofatumumab 62 Xcytrin R 62 Nasulin 62 Pivotal Phase III 62 Pertuzumab 62 LY# [002] 62 oritavancin 62 Diabetic Macular Edema 62 Solazed TM 62 iSONEP 62 farletuzumab 62 OHR/AVR# 62 ELND# 62 pseudobulbar affect PBA 62 apoptosis inducer 62 lumiliximab 62 Clolar ® 62 Monotherapy 61 anti CD# antibodies 61 Picoplatin 61 Tasimelteon 61 Alzhemed TM 61 Naproxcinod 61 evaluating satraplatin 61 nilotinib 61 febuxostat 61 Gleevec resistant 61 cutaneous T cell 61 Velcade bortezomib 61 trastuzumab emtansine T DM1 61 Maribavir 61 bicifadine 61 Trofex 61 Oral NKTR 61 GFT# 61 CTCE 61 Solazed 61 tipifarnib 61 sulodexide 61 Leukine ® 61 Octreotide 61 TRX1 61 CYT# potent vascular disrupting 61 atrasentan 61 Phase III Trials 61 CD3 monoclonal antibody 61 NEUMUNE 61 cell lymphoma CTCL 61 Phase IIb Clinical Trial 61 rALLy clinical trial 61 erlotinib Tarceva 61 sodium thiosulfate STS 61 Campath ® 61 Akt inhibitor 61 molecularly targeted 61 albinterferon alfa 2b 61 RIGScan CR 61 Bafetinib 61 CIMZIA TM 61 Insegia 61 Vidofludimus 61 hormone LHRH antagonist 61 Rigel R# 61 unique alkylating agent 61 bafetinib 61 AAG geldanamycin analog 61 HSP# inhibitor 61 Gabapentin GR 61 microtubule targeting 61 systemic anaplastic large 61 L Annamycin 61 tocilizumab 61 vilazodone 61 Zenvia Phase III 61 triphendiol 61 Tezampanel 61 immunomodulator 61 Augment TM 61 Fludara 61 indolent NHL 61 antiangiogenic 61 UPLYSO 61 nucleoside analog 61 INT# [002] 61 JVRS 61 JAK3 61 adipiplon 61 dasatinib Sprycel 61 ARIKACE 61 oxidative stress inducer 61 immunomodulating 61 Vectibix panitumumab 61 ORENCIA R 61 drug pipeline TAFA# 61 AzaSite Plus 61 multi kinase inhibitor 61 telaprevir VX 61 tiapamil 61 cetuximab Erbitux ® 61 Indaflex TM 61 Reverset 61 omacetaxine 61 Genasense ® oblimersen 61 FASLODEX 61 investigational compounds 61 KNS # 61 Phase III Pivotal 61 Treanda 61 Enzastaurin 61 evaluating Xcytrin 61 multicenter Phase II 61 PKC# 61 Linaclotide 61 Clonicel 61 Ridaforolimus 61 Epidermal Growth Factor Receptor 61 Cutaneous T 61 GRN# 61 Phase IIb clinical trials 61 Squalamine 61 pharmacodynamic properties 61 prucalopride 61 Trabectedin 61 MAP# 61 Zerenex 61 bendamustine 61 SparVax TM 61 R roscovitine 61 CBLB# 61 eculizumab 61 Fodosine 61 PD LID 61 Virulizin ® 61 glatiramer acetate 61 EGFR inhibitors 61 ALN PCS 61 brivaracetam 61 rBChE 61 Phase 2b Study 61 Bevacizumab 61 alefacept 61 pharmacokinetic PK study 61 CIMZIA ™ 61 Maraviroc 61 Arimoclomol 61 ATL/TV# 61 Laquinimod 61 Advanced Renal Cell 61 protein kinase inhibitor 61 Sudhir Agrawal D.Phil 61 Mylotarg 61 insulin sensitizing 61 DU #b 61 UVIDEM 61 demethylating agents 61 Doxorubicin 61 anti amnesic 61 Diamyd ® 61 novel topoisomerase 61 temsirolimus 61 EndoTAGTM 1 61 LibiGel ® 61 bortezomib Velcade ® 61 Phase 2b clinical 61 indibulin 61 Vicinium TM 61 Æterna Zentaris 61 MAA submission 61 Pivotal Study 61 Restanza 61 Hsp# inhibitor 61 mGluR5 NAM 61 IMiDs 61 Enzyme Replacement Therapy 61 Hsp# inhibition 61 AEZS 61 EGFr 61 Nuvion 61 Thiovir 61 sodium Injection 61 XL# anticancer compounds 61 INCB# [003] 61 Fx #A 61 Immunotherapeutic 61 subcutaneous formulation 61 BrachySil TM 61 advanced carcinoid 61 PEGylated Fab fragment 61 refractory multiple myeloma 61 opioid induced bowel dysfunction 61 oral ridaforolimus 61 EP #R 61 ProLindac TM 61 vemurafenib 61 oral proteasome inhibitor 61 Ophena 61 Locteron ® 61 polysaccharide polymer 61 taxanes 61 Zybrestat 61 Elesclomol 61 bosutinib 61 ApoB SNALP 61 anticancer therapies 61 Omnitarg 61 Romiplostim 61 MORAb 61 cetuximab Erbitux 61 Cinryze ™ 61 Fulvestrant 61 Aurexis 61 Loramyc R 61 FRDA 61 Aliskiren 61 Telaprevir 61 RAPAFLO 61 ofatumumab HuMax CD# 61 MEK Inhibitor 61 GLPG# 61 ADP receptor antagonist 61 nalbuphine ER 61 Onrigin 61 gemcitabine cisplatin 61 dosing cohort 61 Telcyta 61 polymerase inhibitor 61 Ophena TM 61 VEGF inhibitors 61 telomerase inhibitor drug 61 IMiDs R 61 Omacetaxine mepesuccinate 61 dirucotide 61 aflibercept 61 refractory Hodgkin lymphoma 61 Randomized Phase 61 NVA# 61 Darinaparsin 61 IIa trial 61 MultiStem 61 R sorafenib tablets 61 Vitaxin 61 PEGPH# 61 ZYBRESTAT fosbretabulin 61 velafermin belinostat 61 SERMs 61 Intravenous CP 61 Everolimus 61 trastuzumab Herceptin 61 Azacitidine 61 GMX# 61 TEMODAL 61 Lixivaptan 61 SAR# [002] 61 Urocidin TM 61 AeroLEF 61 superficial bladder cancer 61 Sphingomab 61 compound PMX # 61 Marqibo TM 61 LEVADEX TM 61 azacitidine 61 MabCampath 61 Metastatic Melanoma 61 vascular disrupting agent 61 Phase 2a Clinical Trial 61 ruxolitinib 61 Targretin capsules 61 therapeutic monoclonal antibody 61 favorable pharmacokinetic profile 61 registrational trials 61 octreotide implant 61 JAK Inhibitor 61 Octreolin 60 ANAVEX #-# [003] 60 ZEVALIN ® 60 ocrelizumab 60 Triapine R 60 FOLFOX chemotherapy 60 oral JAK1 60 forodesine hydrochloride 60 Advexin 60 mifamurtide 60 Anticalin R 60 antibody MAb 60 Revlimid lenalidomide 60 Abiraterone acetate 60 oral anticancer 60 phase IIb 60 AGGRASTAT R 60 PI3K inhibitor 60 IV Busulfex 60 diabetic neuropathic pain 60 YONDELIS R 60 Phase III Trial 60 dexanabinol 60 imatinib Gleevec ® 60 preclinical 60 lapatinib Tykerb 60 immune modulatory 60 generation purine nucleoside 60 baminercept 60 NS5A 60 danoprevir 60 rindopepimut 60 BZL# 60 dose cohort 60 Apaziquone 60 HepeX B 60 CCR9 antagonist 60 dimebon 60 LE DT 60 confirmatory Phase III 60 maximally tolerated dose 60 relapsed SCLC 60 castration resistant prostate cancer 60 tafamidis 60 Fondaparinux 60 REOLYSIN ® 60 BRIM3 60 NUVIGIL 60 IMiDs ® compound 60 OMNARIS Nasal Spray 60 motexafin gadolinium Injection 60 ANYARA 60 INTELENCE 60 Avastin bevacizumab 60 Tavocept 60 PSN# [001] 60 ProSavin 60 AZILECT ® 60 pitavastatin 60 SRT# [003] 60 Phase 2a clinical 60 Pathway Inhibitor 60 Azedra ™ 60 placebo controlled Phase 60 Alemtuzumab 60 mycophenolate mofetil 60 Corlux 60 acyclovir Lauriad R 60 cutaneous T 60 CDK inhibitor 60 Anturol 60 Synavive 60 TKB# 60 Silodosin 60 TMC# [002] 60 MERLIN TIMI 60 ONCASPAR 60 ABILIFY ® 60 LEVADEX 60 Zingo TM 60 ALGRX 60 kinase inhibitor 60 Elvitegravir 60 orally dosed 60 corticosteroid dexamethasone 60 pharmacokinetics pharmacodynamics 60 sitaxsentan 60 Viramidine 60 TPI ASM8 60 Ceflatonin ® 60 low dose cytarabine 60 Firazyr 60 phenoxodiol 60 anticancer agents 60 hypoxia activated prodrug 60 tolevamer 60 riociguat 60 Zenvia ™ 60 gemcitabine 60 5 HT6 60 JAK2 inhibitors 60 hematological cancers 60 PEGylated interferon beta 1a 60 sorafenib Nexavar ® 60 NPC 1C 60 Androxal 60 preclinical efficacy 60 sunitinib 60 Orphan Drug designations 60 romiplostim